Our Portfolio
Export table
FILTERS
Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options
PRODUCT NAME
THERAPEUTIC AREA
PHARMACEUTICAL
FORM
STRENGTH
REFERENCE
PRODUCT
DOSSIER
AVAILABILITY
Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
5/850 mg
5/1000 mg
Xigduo / Astra Zeneca
2022
Alimentary tract & metabolism
Film-coated tablets
10 mg
25 mg
Jardiance / Boehringer Ingelheim
2021
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
2024
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
2022
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
2023
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
2023
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
2022
Antineoplastic & Immunomodulating Agents
Film-coated tablets
5 mg
10 mg
Xeljanz / Pfizer
Early stage
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Early stage
Nervous system
Film-coated tablets
5 mg
10 mg
15 mg
20 mg
Brintellix / H. Lundbeck A/S
2023
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
DISCLAIMER
The above list is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.
Our Portfolio
Empagliflozin* / Linagliptin* NEW!
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Glyxambi/ Boehringer Ingelheim
STRENGTH
10 mg/5 mg
| 25 mg/5 mg
DOSSIER AVAILABILITY
2024
Dapagliflozin* / Metformin (1)
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Xigduo / Astra Zeneca
STRENGTH
5/850 mg
| 5/1000 mg
DOSSIER AVAILABILITY
2022
Empagliflozin* (1)
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Jardiance / Boehringer Ingelheim
STRENGTH
10 mg
| 25 mg
DOSSIER AVAILABILITY
2021
Empagliflozin* / Metformin
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Synjardy / Boehringer Ingelheim
STRENGTH
5mg/500mg
| 5mg/850mg
| 5mg/1000 mg
| 12.5mg/500mg
| 12.5mg/850mg
| 12.5mg/1000mg
DOSSIER AVAILABILITY
2024
Linagliptin* / Metformin (2)
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Jentadueto / Boehringer Ingelheim
STRENGTH
2.5/500 mg
| 2.5/850 mg
| 2.5/1000 mg
DOSSIER AVAILABILITY
2022
Nebivolol
THERAPEUTIC AREA
Cardiovascular System
PHARMACEUTICAL FORM
Tablets
REFERENCE PRODUCT
Nebilet / Menarini
STRENGTH
5 mg
| 10 mg
DOSSIER AVAILABILITY
2022
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
